Table 6.
Selonsertib did not affect ABCC10-mediated MDR.
| Treatment | IC50 ± SDa (RFb) |
|
|---|---|---|
| HEK293/pcDNA3.1 (μM) | HEK293/ABCC10 (μM) | |
| Paclitaxel | 0.041 ± 0.005 (1.00) | 0.457 ± 0.146 (11.15) |
| +Selonsertib (3 μM) | 0.043 ± 0.002 (1.05) | 0.611 ± 0.105 (14.90) |
| +Selonsertib (10 μM) | 0.037 ± 0.002 (0.90) | 0.460 ± 0.177 (11.22) |
| +Cepharanthine (10 μM) | 0.038 ± 0.003 (0.93) | 0.054 ± 0.005 (1.32)* |
| Cisplatin | 1.042 ± 0.645 (1.00) | 1.313 ± 0.731 (1.26) |
| +Selonsertib (3 μM) | 1.124 ± 0.728 (1.08) | 1.137 ± 0.540 (1.09) |
| +Selonsertib (10 μM) | 1.132 ± 0.635 (1.09) | 1.346 ± 0.649 (1.29) |
| +Cepharanthine (10 μM) | 1.153 ± 0.669 (1.11) | 1.238 ± 0.373 (1.19) |
*
indicates p < 0.05 versus group treated with antineoplastic drug only.
a
IC50 values were determined by MTT assay as described in “materials and methods”, and were obtained from three independent experiments in triplicate.
b
Resistance fold (RF) was calculated from dividing the IC50 values of parental cells or resistant cells by the IC50 of parental cells in the absence of selonsertib or positive control inhibitor.